Correlation Engine 2.0
Clear Search sequence regions

  • adult (1)
  • beta lactamases (2)
  • HABP (1)
  • humans (1)
  • patients (1)
  • pneumonia (3)
  • sulbactam (8)
  • switzerland (1)
  • VABP (1)
  • Sizes of these terms reflect their relevance to your search.

    Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Coadministration of durlobactam (a β-lactamase inhibitor with potent activity against a broad range of serine β-lactamases) with sulbactam (an established class A β-lactamase inhibitor with antibacterial activity against A. baumannii) prevents sulbactam degradation by ABC-produced β-lactamases. In May 2023, sulbactam/durlobactam was approved in the USA for use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of ABC. This article summarizes the milestones in the development of sulbactam/durlobactam leading to this first approval for the treatment of infections caused by ABC. © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.


    Susan J Keam. Sulbactam/Durlobactam: First Approval. Drugs. 2023 Sep;83(13):1245-1252

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 37523122

    View Full Text